Victory Capital Management Inc. Reduces Position in Pediatrix Medical Group, Inc. (NYSE:MD)

Victory Capital Management Inc. trimmed its position in Pediatrix Medical Group, Inc. (NYSE:MD) by 26.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 45,429 shares of the company’s stock after selling 16,527 shares during the quarter. Victory Capital Management Inc. owned 0.05% of Pediatrix Medical Group worth $343,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MD. Invenomic Capital Management LP grew its position in shares of Pediatrix Medical Group by 93.3% in the 4th quarter. Invenomic Capital Management LP now owns 1,377,951 shares of the company’s stock worth $12,815,000 after buying an additional 664,955 shares during the period. Boston Partners grew its holdings in Pediatrix Medical Group by 34.0% in the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after purchasing an additional 453,254 shares during the period. Clark Estates Inc. NY bought a new position in shares of Pediatrix Medical Group during the fourth quarter valued at approximately $3,302,000. Vanguard Group Inc. lifted its holdings in shares of Pediatrix Medical Group by 1.6% during the first quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock valued at $105,892,000 after purchasing an additional 164,333 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Pediatrix Medical Group by 10.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,634,065 shares of the company’s stock worth $15,197,000 after purchasing an additional 148,600 shares in the last quarter. 97.71% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. UBS Group increased their price objective on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a research report on Friday, August 9th. Deutsche Bank Aktiengesellschaft upgraded shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating and set a $8.00 price target on the stock in a report on Friday, June 7th. StockNews.com raised Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th. Finally, Truist Financial increased their target price on Pediatrix Medical Group from $8.00 to $10.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Six analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.30.

Insider Activity

In other news, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now owns 30,805 shares of the company’s stock, valued at $343,783.80. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now directly owns 30,805 shares in the company, valued at $343,783.80. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO James D. Swift sold 11,100 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $10.79, for a total value of $119,769.00. Following the transaction, the chief executive officer now owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 68,100 shares of company stock valued at $701,889. 2.00% of the stock is currently owned by insiders.

Pediatrix Medical Group Stock Performance

Shares of NYSE MD opened at $10.48 on Tuesday. The company has a market cap of $881.86 million, a P/E ratio of -12.33, a P/E/G ratio of 1.68 and a beta of 1.56. Pediatrix Medical Group, Inc. has a 52-week low of $6.62 and a 52-week high of $13.01. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.38 and a current ratio of 1.38. The firm’s fifty day moving average is $9.78 and its two-hundred day moving average is $8.83.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Tuesday, August 6th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.03. The firm had revenue of $504.30 million during the quarter, compared to the consensus estimate of $505.49 million. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. The company’s quarterly revenue was up .7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.37 EPS. As a group, analysts anticipate that Pediatrix Medical Group, Inc. will post 1.18 EPS for the current fiscal year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.